Agios Pharmaceuticals (AGIO) EBIT Margin (2012 - 2026)
Agios Pharmaceuticals (AGIO) posted EBIT Margin of 530.34% for Q1 2026, up 12.9% on a QoQ basis from 608.89% in Q4 2025, and up 69163.0% year-over-year from N/an in Q1 2025.
Agios Pharmaceuticals (AGIO) EBIT Margin (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals' EBIT Margin history runs 14 years deep, the most recent figure standing at 530.34% for Q1 2026.
- Quarterly EBIT Margin rose 69163.0% year-over-year to 530.34% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 719.97% (up 46889.0% YoY) and the FY2025 annual result came in at 873.87%, up 29260.0% from the prior year.
- EBIT Margin was 530.34% for Q1 2026 at Agios Pharmaceuticals, up from 608.89% in the prior quarter.
- Across five years, EBIT Margin topped out at 530.34% in Q1 2026 and bottomed at 12156.85% in Q1 2022.
- A 5-year average of 1977.81% and a median of 1228.29% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2023 — EBIT Margin surged 1054136 bps — and 2025, when it tumbled 9763 bps.
- Agios Pharmaceuticals' EBIT Margin stood at 2300.97% in 2022, then surged by 35 bps to 1496.23% in 2023, then grew by 22 bps to 1165.3% in 2024, then soared by 48 bps to 608.89% in 2025, then advanced by 13 bps to 530.34% in 2026.
- Business Quant data shows AGIO's EBIT Margin at 530.34% in Q1 2026, 608.89% in Q4 2025, and 907.37% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Agios Pharmaceuticals | 2.13 Bn | 2.13 Bn | 19.43 Mn | -530.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -530.34% |
| Dec 31, 2025 | -608.89% |
| Sep 30, 2025 | -907.37% |
| Jun 30, 2025 | -1,020.12% |
| Mar 31, 2025 | -1,221.97% |
| Dec 31, 2024 | -1,165.30% |
| Sep 30, 2024 | -1,146.93% |
| Jun 30, 2024 | -1,228.29% |
| Mar 31, 2024 | -1,124.34% |
| Dec 31, 2023 | -1,496.23% |
| Sep 30, 2023 | -1,363.66% |
| Jun 30, 2023 | -1,396.01% |
| Mar 31, 2023 | -1,615.49% |
| Dec 31, 2022 | -2,300.97% |
| Sep 30, 2022 | -2,590.73% |
| Jun 30, 2022 | -1,749.19% |
| Mar 31, 2022 | -12,156.85% |
| Dec 31, 2020 | -209.86% |
| Sep 30, 2020 | -231.34% |
| Jun 30, 2020 | -222.95% |